|
gptkbp:instanceOf
|
antiviral drug
|
|
gptkbp:activeIngredient
|
gptkb:artemether
gptkb:lumefantrine
|
|
gptkbp:approvedBy
|
gptkb:World_Health_Organization
gptkb:U.S._Food_and_Drug_Administration
1999
|
|
gptkbp:ATCCode
|
gptkb:P01BE02
|
|
gptkbp:contraindication
|
severe malaria
hypersensitivity to artemether or lumefantrine
|
|
gptkbp:developedBy
|
gptkb:Novartis
|
|
gptkbp:effect
|
gptkb:Plasmodium_falciparum
|
|
gptkbp:form
|
gptkb:tablet
fixed-dose combination
|
|
gptkbp:halfLife
|
artemether: 1-3 hours
lumefantrine: 3-6 days
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Coartem
|
|
gptkbp:marketedIn
|
over 80 countries
|
|
gptkbp:mechanismOfAction
|
inhibits nucleic acid and protein synthesis in Plasmodium
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:prescriptionStatus
|
prescription only
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
vomiting
anorexia
dizziness
headache
palpitations
arthralgia
myalgia
|
|
gptkbp:usedFor
|
treatment of malaria
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
included
|
|
gptkbp:bfsParent
|
gptkb:artemether
|
|
gptkbp:bfsLayer
|
6
|